102940 — Kolon Life Science Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩292bn
- KR₩391bn
- KR₩125bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 20,914 | 15,031 | 27,910 | 6,371 | 7,480 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 29,507 | 22,647 | 20,304 | 30,029 | 25,634 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 95,290 | 100,563 | 98,021 | 110,184 | 105,045 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 178,398 | 141,893 | 131,481 | 125,960 | 123,138 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 278,295 | 248,338 | 234,658 | 314,118 | 309,436 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 126,173 | 145,152 | 95,469 | 109,578 | 128,341 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 177,274 | 190,381 | 135,248 | 146,395 | 171,764 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Total Equity | 101,020 | 57,957 | 99,410 | 167,723 | 137,672 |
Total Liabilities & Shareholders' Equity | 278,295 | 248,338 | 234,658 | 314,118 | 309,436 |
Total Common Shares Outstanding |